Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.69 |
| ▸ | GAA | P10253 | 5/20 | 0.69 |
| ▸ | HTT | P42858 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30166016 | 1.00 | MAPT (0.69) | MAPTGAAHTTHSD17B10KDM4E | |
| SCHEMBL3597080 | 0.82 | MAPT (1.00) | MAPTGAAHTTHSD17B10KDM4E | |
| SCHEMBL7711166 | 0.80 | TSHR (0.49) | MAPTGAAHTTHSD17B10KDM4E | |
| SCHEMBL10608182 | 0.79 | MAPT (0.48) | MAPTGAAHTTHSD17B10KDM4E | |
| SCHEMBL29372731 | 0.79 | LMNA (0.56) | MAPTGAAHTTHSD17B10TP53 | |
| SCHEMBL27988230 | 0.78 | MAPT (0.49) | MAPTGAAKDM4ELMNAPOLB | |
| SCHEMBL17696404 | 0.78 | MAPT (0.69) | MAPTGAAHTTHSD17B10KDM4E | |
| Phosphine SCHEMBL22345943 | 0.77 | MAPT (0.48) | MAPTGAAKDM4ELMNAPOLB | |
| SCHEMBL11511170 | 0.77 | KMT2A (0.54) | MAPTGAAHSD17B10KDM4ELMNA | |
| SCHEMBL29370930 | 0.76 | GAA (0.51) | MAPTGAAHTTHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0784042-B1 | Use of hydrogen bis(oxalato)borate | DSM IP ASSETS BV (NL) | 2009-05-27 | — | — | EP | claimed |
| US-5886196-A | Method of catalyzing condensation reactions | ROCHE VITAMINS INC. (US) | 1999-03-23 | — | — | US | claimed |
| CN-1161251-A | Use of hydrogen-bis (oxalato) borate | HOFFMANN LA ROCHE (CH) | 1997-10-08 | — | — | CN | claimed |
| JP-9192493-A | — | — | None | — | — | JP | disclosed |
| US-12139456-B2 | Vitamin K2 synthesis | DSM IP ASSETS B.V. (NL) | 2024-11-12 | — | — | US | disclosed |
| CN-115151524-B | Vitamin K2 synthesis | 帝斯曼知识产权资产管理有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20230159429-A1 | VITAMIN K2 SYNTHESIS | DSM IP ASSETS B.V. (NL) | 2023-05-25 | — | — | US | disclosed |
| WO-2020035601-A1 | SYNTHESIS OF CHROMANOL AND 2-METHYL-1,4-NAPHTHOQUINONE DERIVATIVES | BASF SE (DE) | 2020-02-20 | — | — | WO | disclosed |
| CN-1099911-C | Use of hydrogen-bis (oxalato) borate | HOFFMANN LA ROCHE (CH) | 2003-01-29 | — | — | CN | disclosed |
| US-5886196-A | Method of catalyzing condensation reactions | ROCHE VITAMINS INC. (US) | 1999-03-23 | — | — | US | disclosed |
| CN-1161251-A | Use of hydrogen-bis (oxalato) borate | HOFFMANN LA ROCHE (CH) | 1997-10-08 | — | — | CN | disclosed |
| JP-H09192493-A | BID(OXALATO)BORATE | F HOFFMANN LA ROCHE AG | 1997-07-29 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159429-A1 | VITAMIN K2 SYNTHESIS | PROC, VKORC1, VKORC1L1 | MAPT 4099/4885GAA 4410/4885HTT 4186/4885 |
| US-12139456-B2 | Vitamin K2 synthesis | PROC, VKORC1, VKORC1L1 | MAPT 4099/4885GAA 4410/4885HTT 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.